Showing results (391-400 of 642) with videos related to

Sort By:
Pageof 65
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1989
Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivoT H Kramer, J E Shook, W Kazmierski, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 1999
Biological activity of fragments and analogues of the potent dimeric opioid peptide, biphalinA W Lipkowski, A Misicka, P Davis, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|April 1, 1995
Molecular biology and pharmacology of cloned opioid receptorsR J Knapp, E Malatynska, N Collins, et al.
British Journal of Pharmacology|October 28, 2010
Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced toleranceT M Largent-Milnes, T Yamamoto, P Nair, et al.
Life Sciences|June 13, 2003
Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of painV J Hruby, R S Agnes, P Davis, et al.
Endocrinology|August 1, 1996
Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des- Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonistsB A Van Tine, B Y Azizeh, D Trivedi, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|August 15, 1996
Melanocortin antagonists define two distinct pathways of cardiovascular control by alpha- and gamma-melanocyte-stimulating hormonesS J Li, K Varga, P Archer, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1990
A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneityR J Knapp, L K Vaughn, S N Fang, et al.
Life Sciences|January 1, 1983
Cyclic penicillamine containing enkephalin analogs display profound delta receptor selectivitiesH I Mosberg, R Hurst, V J Hruby, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 1, 1994
Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: evidence for delta opioid receptor heterogeneityL Fang, R J Knapp, R Horvath, et al.
Pageof 65